UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices)
(
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 30, 2022, Sharps Technology, Inc. (the “Company”) entered into a formal employment agreement (the “Agreement”) with Andrew R. Crescenzo (age 65), who has been serving as the Company’s Chief Financial Officer (CFO) on a contract services basis for the last three years.
Mr. Crescenzo’s term as the Company’s CFO will begin on September 30, 2022, and continue until terminated by either party, subject to the terms of the Agreement (the “Term”). For his services, Mr. Crescenzo will be paid $225,000 a year and shall receive a one-time $18,750 incentive payment upon the commencement of the Agreement. During the course of the Term, Mr. Crescenzo will be eligible for (i) performance bonuses to be granted at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s 2022 Equity Incentive Plan. The Agreement contains a perpetual confidentiality covenant as well as non-competition and employee and customer non-solicitation covenants that apply during the Term and for a period of one year following Mr. Crescenzo’s termination.
Before joining the Company as CFO in May 2019 under a consulting agreement with CFO Consulting Partners LLP, Mr. Crescenzo served in various finance roles in the biotech, manufacturing and distribution industries. From 2014 to 2016, he was CFO of United Metro Energy and from 2006 to 2014, he served as Senior VP of Finance at Enzo Biochem (NYSE:ENZ). Prior to 2006, Mr. Crescenzo was an Executive Director (2002-2006) and a Senior Manager (1997-2002) at Grant Thornton LLP. Mr. Crescenzo is a Certified Public Accountant and received his Bachelor of Business Administration from Adelphi University.
There are no other arrangements or understandings between Mr. Crescenzo and any other person pursuant to which Mr. Crescenzo was appointed CFO of the Company. There are also no family relationships between Mr. Crescenzo and any director or executive officer of the Company, and Mr. Crescenzo has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The foregoing is a summary description of the Agreement. For a full description, please refer to the copy of the Agreement that is incorporated by reference and filed herewith as Exhibit 10.1.
| Item 9.01 | Exhibits |
Exhibit No. |
Description | |
| 10.1 | Employment Agreement, dated September 30, 2022, by and between Sharps Technology, Inc., and Andrew R. Crescenzo | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 6, 2022
| SHARPS TECHNOLOGY, INC. | |
| /s/ Robert M. Hayes | |
| Robert M. Hayes | |
| Chief Executive Officer |
Exhibit 10.1
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”) states the terms and conditions that govern the contractual agreement between Andrew R. Crescenzo (the “Executive”) having his principal place of residence at 80 Merritt Ave, Massapequa, New York and Sharps Technology, Inc. located at 105 Maxess Road STE 124, Melville, New York (the “Company”) who both agree to be bound by this Agreement.
WHEREAS, the Executive is very experienced in the field of accounting, controls, systems, audit, sec filing, and related subjects; and
WHEREAS, the Executive has filled the role of Chief Financial Officer of Sharps Technology, Inc. for the past three years as a contract services person through CFO Consulting Partners, LLP; and
WHEREAS, the Company has negotiated a fee with CFO Consulting Partners to permit the Executive to join the Company on a full time basis; and
WHEREAS, the Executive is available and now has no prohibitions in performing the services as described in this Agreement; and
WHEREAS, the parties have negotiated the terms of this Agreement and believe the terms to be fair and reasonable; and
WHEREAS, the Company desires to retain the service of the Executive to render the services as the Chief Financial Officer of the Company.
NOW, THEREFORE, in consideration of the mutual covenants and promises made by the parties hereto, the Executive and the Company (individually), each a “Party” and collectively, the “Parties”) covenant and agree as follows:
1. TERM
This Agreement shall replace all prior agreements with Andrew R. Crescenzo, and commence on September 30, 2022, and continue until terminated by either Party, subject to the following terms.
Either Party may terminate this Agreement for any reason with 90 days written notice to the other Party. Termination for cause will have immediate effect and include gross negligence or theft of the Company’s property. If terminated with cause, the Executive shall be paid all compensation accrued through the termination notice date.
| 1 |
2. EMPLOYMENT SERVICES
The Executive agrees that he shall provide his full-time energy and expertise to the Company as Chief Financial Officer and perform all duties assigned to him in that role. The Executive confirms there are no obligations which would prevent his carrying out all the responsibilities of the Employment Services in this Agreement.
3. COMPENSATION
In consideration for the Employment Services, the Company shall pay the Executive at the rate of $225,000 (two hundred twenty-five thousand dollars) per year. Compensation shall be paid via the Company’s payroll. Payment shall be made semi-monthly electronically, to the Executive’s designated account, on or about the 15th and 30th of each month. At the commencement of the Agreement, the Company will pay the Executive $18,750 as an incentive.
BUSINESS EXPENSES
Reimbursement of ordinary expenses in accordance with policy and approved by the Company.
BENEFITS AND PREQUISITES
During the Employment Term, the Executive shall be entitled to fringe benefits and perquisites consistent with those provided to similarly situated executives of the Company.
| a. | Employee Benefits. During the Employment Term, the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect from time to time on a basis which is no less favorable than is provided to other similarly situated Executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee Benefit Plans. | |
| During the Employment Term, the Executive shall be entitled to family health insurance benefits to the extent consistent with applicable law and the terms of the applicable Employee Benefit Plan. Alternatively, if the Executive is under Medicare and other supplemental plans, the Company will reimburse $1,000 per month. |
| 2 |
PERFORMANCE BONUS
The board of directors, through its Compensation Committee shall review the performance of the Chief Financial Officer along with the CEO and COO of the Company and determine, in their sole discretion the performance bonus of the Executive.
EQUITY AWARDS
During the Employment Term, the Executive shall be eligible to participate in the 2022 Equity Incentive Plan or any successor plan, subject to the terms of the 2022 Equity Incentive Plan or successor plan, as determined by the Board or the Compensation Committee, in its discretion. All terms of the Equity Awards will be included in the award letter provided and signed by the Executive and the Company.
4. INTELLECTUAL PROPERTY RIGHTS IN WORK PRODUCT
The Parties acknowledge and agree that the Company will hold all intellectual property rights in any work product resulting from the Employment Services including, but not limited to, copyright, patent, and trademark rights. The Executive agrees not to claim any such ownership in such work product’s intellectual property at any time prior to or after the completion and delivery of such work product to the Company.
5. CONFIDENTIALITY
The Executive shall not disclose to any third party any Confidential details regarding the Company’s business, including, without limitation any information regarding any of the Company’s customer information, business plans, or price points (the “Confidential Information”), (ii) make copies of any Confidential Information or any content based on the concepts contained with the Confidential Information for personal use or for distribution unless in the best interest of the Company, or (iii) use Confidential Information other than solely for the benefit of the Company.
6. NONCOMPETITION
During the term of this Agreement and for 24 months thereafter, the Executive shall not engage, directly or indirectly, as an executive, employee, officer, manager, partner, consultant, agent, owner or in any other capacity, in any direct competition with the Company or any of its subsidiaries, in the safety syringe field.
| 3 |
7. NONSOLICITATION OF CUSTOMERS
During the term of this Agreement and for 24 months thereafter, the Executive will not, directly, or indirectly, solicit or attempt to solicit any business of the Company, from any of the Company’s clients, prospects, employees, or contractors.
8. NONSOLICITATION OF EMPLOYEES
During the term of this Agreement and for 24 months thereafter, the Executive will not, directly, or indirectly, recruit, solicit, or induce, or attempt to recruit, solicit, or induce, any of the Company’s employees, or contractors for work at another company.
9. NO MODIFICATION UNLESS IN WRITING
No modification of this agreement shall be valid unless in writing and agreed upon by both Parties.
10. APPLICABLE LAW
This Employment Agreement and the interpretation of its terms shall be governed by and construed in accordance with the laws of the State of New York and subject to the exclusive jurisdiction of the federal and state courts located in New York City.
IN WITNESS WHEREOF, each of the Parties have agreed to this Agreement
| Sharps Technology, Inc., as Company | ||
| By: | /s/ Andrew R. Crescenzo | |
| Date: | ||
| Andrew R. Crescenzo, as Executive | ||
| By: | ||
| Date: - 9/30/22 | ||
| 4 |